Press

COMPASS Pathways plc to announce second quarter 2021 financial results on 11 August 2021

Aug 6 • 2 min read

Quick Take: Compass Pathways will announce their second quarter financial results on August 11. COMPASS Pathways plc (Nasdaq: CMPS), a mental health care company dedicated to accelerating patient access to evidence-based innovation in mental health, announced today that it will release financial results for the second quarter 2021, and provide an update on recent business…

PharmaDrug Forms Research Collaboration with Terasaki Institute for Novel Ocular Drug Formulation Program to Deliver DMT and Other Tryptamines to Treat Eye Disease

Aug 5 • 4 min read

Quick Take: PharmaDrug has formed a partnership with a biotechnology institute to research DMT therapy for eye diseases. PharmaDrug Inc. (CSE: PHRX), a specialty pharmaceutical company focused on the research, development and commercialization of controlled-substances and natural medicines such as psychedelics, cannabis and naturally-derived approved drugs, is pleased to announce that PharmaDrug has entered into…

Cybin to Commence Trading on the NYSE American on August 5

Aug 5 • 2 min read

Quick Take: Cybin will begin trading on the NYSE today under the ticker “CYBN” Cybin Inc. (NEO:CYBN), a biotechnology company focused on progressing psychedelic therapeutics, today announced that its common shares will open for trading on the NYSE American LLC stock exchange (“NYSE American”)on August 5, 2021, under the symbol “CYBN”. In addition to listing…

Awakn Life Sciences Announces Its Second Location in the UK for “Awakn Clinics London,” Providing Treatment to the Largest City in the UK

Aug 4 • 3 min read

Quick Take: Awakn has announced its plans to open a psychedelic treatment clinic in the city of London. Awakn Life Sciences Corp. (NEO: AWKN), a biotechnology company with clinical operations developing and delivering psychedelic medicines to better treat Addiction, today announced the signing of its 10-year lease to open Awakn Clinics London, a psychedelic-focused therapy…

Tryp Therapeutics to Present at Canaccord Genuity Annual Growth Conference

Aug 3 • 2 min read

Quick Take: Tryp Therapeutics is slated to present at the Canaccord Genuity Annual Growth Conference. Tryp Therapeutics (CSE: TRYP), a pharmaceutical company focused on developing psilocybin-based compounds for diseases with unmet medical needs through accelerated regulatory pathways, announced today that it will present at the Canaccord Genuity Virtual Growth Conference. The conference will be held virtually…

Pages: 123456789101112131415161718192021222324252627282930313233343536373839404142434445464748495051525354555657585960616263646566676869707172737475767778798081828384858687888990919293949596979899100101102103104105106107108109110111112113114115116117118119120121122123124125126127128129130131132133134135136137138139140141142143144145146147148149150151152153154155156157158159160161162163164165166167168169170171172173174175176177178179180181182183184185186187188189190191192193194195196197198199200201202203204205206207208209210211212213214215216217218219220221222223224225226227228229230231232233234235236237238239240241242243244245246247248249250251252253254255256257258259260261262263264265266267268269270271272273274275276277278279280281282283284285286287288289290291292293294295296297298299300301302303304305306307308309310311312313314315316317318319320321322323324325326327328329330331332333334335336337338339340341342343344345346347348349350351352353354355356357358359360361362363364365366367368369370371372373374375376377378379380381382383384385386387388389390391392393394395396397398399400401402403404405406407408409410411412413414415416417418419420421422423424425426427428429430431432433434435436437438439440441